scilogo.jpg
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
January 04, 2024 07:18 ET | SciSparc Ltd
The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of...
NeuroQure Logo.png
NeuroQure Acquires Patents to Detect Autism in Newborns with a Skin Sample
December 13, 2023 09:30 ET | NeuroQure
IRVINE, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- NeuroQure, a pioneering biotech startup specializing in gene therapy for neurocognitive disorders, has reached a pivotal milestone in the...
scilogo.jpg
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
December 13, 2023 08:18 ET | SciSparc Ltd
MitoCareX Bio met its second milestone as part of its joint venture agreement with the Company TEL AVIV, Israel, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
Lindsey Sneed
Study: Autistic Children May Need Fewer Hours of Treatment Than Previously Thought
November 21, 2023 13:41 ET | Catalight
Walnut Creek, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Each year, tens of thousands of parents and caregivers of children with autism spectrum disorder (ASD) face vital decisions: What kind of...
NeuroQure Logo.png
Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
November 06, 2023 12:00 ET | NeuroQure
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum...
scilogo.jpg
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
October 24, 2023 07:20 ET | SciSparc Ltd
The Company's most recent patent further solidifies its position within the cannabis sector, complementing existing grants in the U.S., Europe, and other key jurisdictions  TEL AVIV, Israel, Oct. ...
Verbal Beginnings to Open New Early Intervention Comprehensive Autism Services Center in Frederick, MD
August 09, 2023 09:00 ET | Verbal Beginnings
FREDERICK, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Verbal Beginnings, a leading provider of comprehensive Autism services is thrilled to announce the opening of a new location in Frederick, Maryland,...
PharmAla Biotech Logo 800 x 422.png
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
July 20, 2023 09:07 ET | PharmAla Biotech
VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
LOGO.png
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
October 07, 2022 09:20 ET | The Greater Cannabis Company, Inc.
BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid...
Zynerba_Logo-spot_coated_flat_tagline-01.png
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
May 27, 2020 06:45 ET | Zynerba Pharmaceuticals, Inc.
- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist - - Safety Data Reinforce...